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Objective: This clinical study evaluated prospectively adverse events immediately following ultrasound-guided foam
sclerotherapy (UGFS) for the treatment of lower extremity venous valvular insufficiency. Incidence of side effects
associated with carbon dioxide (CO2) foam was compared with a historical control using air-based foam. The literature
on the subject was reviewed.
Methods: Vital signs were monitored during and immediately after UGFS, and adverse events were recorded for 24 hours
following the procedure. The air-based foam group had 49 patients: 44 women and 5 men. The CO2-based foam group
had 128 patients: 115 women and 13 men. CEAP class was C2EpAsPr, describing varicose veins, primary etiology, and
saphenous reflux. UGFS followed thermal ablation of the great saphenous vein. Foam was prepared using the three-way
tap technique to mix gas with 1% polidocanol in a 4:1 ratio. Segments of the great and small saphenous veins and their
tributaries were treated with UGFS. Foam volumes injected were 27  10 (SD) (6-46 range) and 25  12 (6-57 range)
mL for air- and CO2-based foams respectively (P  .39). Incidence of adverse events was compared by 2 statistics. Vital
signs were compared by paired t test.
Results: During the procedure, the average heart rate decreased by less than 5 bpm for both groups (P < .001), and blood
pressure decreased by less than 3 mm Hg in the CO2 group (P < .02). Respiratory rate, electrocardiogram, and pulse
oxymetry did not change significantly in both air- and CO2-foam series (P > .05). Visual disturbances were experienced
by 3.1% (4/128) and 8.2% (4/49) patients in the CO2 and air groups respectively (P  .15). Respiratory difficulties or
circumoral paresthesia each occurred in 0.8% (n  1) of the CO2 patients. Incidence of chest tightness (3.1% vs 18%), dry
cough (1.6% vs 16%), or dizziness (3.1% vs 12%) were significantly lower in the CO2 vs air groups (P < .02). Nausea
occurred in 2% and 4% of the CO2 and air-based foam groups (P  .53). Overall, the proportion of patients describing
side effects decreased from 39% (19/49) to 11% (14/128) as CO2 replaced air for foam preparation (P < .001). Similar
findings were described in the literature of air-based foam but data on the use of physiological gas were rare.
Conclusions: Side effects decreased significantly if CO rather than air was employed to make the sclerosing foam for2 
chemical ablation of superficial veins of the lower extremity. ( J Vasc Surg 2008;47:830-6.)Endovenous chemical ablation, ultrasound-guided
foam sclerotherapy (UGFS) in particular, has become a
common treatment of patients with chronic venous valvular
insufficiency.1,2 The foam is produced by agitating a gas with
a detergent, liquid sclerosant. Air has been commonly em-
ployed but a more physiological gas such as carbon dioxide
(CO2) may have certain advantages.
1-7 Foam can be prepared
in a variety of ways to treat small or large veins,2,8 improves
ultrasound (US) visualization of the venous lumen, i s more
effective than liquid at lower dosages of sclerosant, and has
become an efficient alternative to venous phlebectomy or
stripping.4,6,7,9-16
Patients of all abnormal, clinical, CEAP classes have
been treated with UGFS.1,2,4,6,7,11-14,16-28 Foam sclero-
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830therapy has been used to successfully treat: (1) saphenous
veins primarily, (2) to complement, complete, or extend
stripping or thermal ablation by laser or radiofrequency, (3)
recurrent veins, (4) venous malformations, (5) venous an-
eurysms, (6) sciatic nerve varices, and (7) saphenous or
nonsaphenous perforating veins.1-31
Side effects and adverse events have been described not
only for UGFS but for all methods of treating the superfi-
cial veins of the lower extremity, surgical or nonsurgi-
cal.1-35 The gas in the foam may have the potential for local,
pulmonary, visual and/or cerebral effects, particularly in a
patient with a patent foramen ovale or other, right-to-left
shunt. W e have tracked foam, or gas bubbles, to the right
and left chambers of the heart and to the middle cerebral
artery using transcutaneous, transthoracic echo (TTE),
and transcranial Doppler (TCD).36 In the initial phase of
our experience, the safety profile of air-based polidoca-
nol foam was evaluated in-house. Contemplating the use
of a more physiological gas, CO2, an investigation was
repeated for CO2-based foam. Therefore, this cohort
study, with comparison with historical control, focused
on two primary objectives: (1) to evaluate possible tox-
icity and complications of CO2-based foam; and (2) to
compare the safety profiles obtained for CO2 vs air as two
distinct gases used in UGFS.
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A prospective study was designed to investigate the
incidence of side effects and adverse reactions of a carbon
dioxide (CO2)-based foam for chemical ablation in the
treatment of chronic venous valvular insufficiency. The
results were compared with a similar prospective investiga-
tion previously performed to evaluate air-based foam.
Patient population. Subjects who were candidates for
chemical ablation received instructions about polidocanol,
its use in Europe, Canada, and the United States, its status
with the Federal and Drug Administration (FDA), and
potential alternative treatments. Patients signed informed
consents for treatment with polidocanol and for participa-
tion in the quality assurance research program.
Subjects entered either study after thermal ablation of
the great saphenous vein (GSV). Thermal ablation was
performed either with laser or radio-frequency. The GSV
was occluded to the saphenofemoral junction (SFJ). Con-
current ambulatory phlebectomy was performed as indi-
cated for the treatment of varicose veins. Tributaries of the
SFJ were not treated. Other abnormal, superficial veins
remained patent after the initial GSV ablation. The thermal
ablation procedure was followed by chemical ablation at
one-week to eliminate (1) the GSV distal to the ablated
segment, (2) saphenous tributaries, (3) a refluxing small
saphenous vein, (4) other superficial veins with reflux or
with potential to be part of a refluxing network, and/or (5)
some unablated or recanalized segment of the GSV previ-
ously treated.
Investigations of air- and CO2-based foams included
49 and 128 patients: 44 women and 5men and 115women
and 13 men, respectively. Predominance of female gender
had a 9:1 ratio. The subjects evaluated represented com-
mon patients seen in a phlebology outpatient clinic of a
thriving urban community. Young adults to active retired
people were treated. Average age of the air-based foam
group was 52  12 (SD), ranging from 23 to 80 years.
Average age of the CO2-based foam group was 52  11
(SD), ranging from 29 to 89 years. The CEAP classification
of both groups was C2EpAsPr describing varicose veins,
primary etiology, and saphenous anatomy with reflux last-
ing longer than 500 msec.
Foam preparation. A liquid sclerosant, polidocanol,
was mixed with gas in a 4:1 gas/liquid ratio. Liquid poli-
docanol was diluted to 1%. In the initial safety profile study,
the gas employed was air. In this update, carbon dioxide
(CO2) was mixed with liquid polidocanol. The three-way
tap technique described by Tessari was employed to pre-
pare the foam.17
Foam injection. Foamwas injected under ultrasound-
guidance. The first injection was performed distally. Foam
progression was followed by ultrasound to determine the
site of the following injection. Injections were stopped
once foam approached a connection to the deep venous
system.
Foam volumes. The average volume of air-based foam
injected was 27  10 (SD) mL, ranging from 6 to 46 mL.The average volume of CO2-based foam injected was 25
12 (SD) mL, ranging from 6 to 57 mL. The end point of
treatment was the perceived injection of foam by ultra-
sound in the various venous segments selected for treat-
ment. Total volume injected became a theoretical end-
point since the volumes injected in these studies exceeded
the maximum volumes described by other investigators.11
Patient monitoring. A registered nurse (RN) moni-
tored vital signs at various times: (1) preinjection; (2) every
15 minutes during the injection procedure; and (3) 30 and
60 minutes after the procedure was terminated. The fol-
lowing vital signs were monitored: systolic and diastolic
blood pressures, heart rate, respiratory rate, electrocardio-
gram (ECG), and pulse oximetry.
The RN also monitored and registered sequelae, side
effects, complications and/or patients statements of un-
usual sensations every 15 minutes during the procedure
and ½, 1, 2, 4-6, and 24 hours after the procedure. The
expected sequelae were: (1) injection site itching; and (2)
localized leg pain. Side effects or complications specifically
monitored for were: (1) chest tightness; (2) dry cough; (3)
metallic/medicinal taste; (4) nausea; (5) dizziness; (6)
circumoral paresthesia, (7) respiratory difficulty; and (8)
visual disturbance. All nurses involved with the study had
up to 10 years of extensive experience dealing with patients
being treated for chronic venous insufficiency in an outpa-
tient setting. A patient-supporting role was an intrinsic part
of their participation. Besides being available to counsel the
patients and address their questions and concerns about the
treatment being performed, the nurses were instructed to
ask the patients to describe their condition at set intervals;
they did not volunteer an answer or ask specific questions
about the items mentioned above. Suggestions were
avoided but, in contrast, the patients had freedom to ex-
press their concerns and unusual sensations. The phrases
used by the patients were then recorded and compared with
the closest item in the list. For example, aching was classi-
fied as leg pain. The 2-hour, 4-6-hour, and 24-hour inter-
views were conducted by phone. Although not “blind” to
the gas used, the RNs in the clinic had no apparent reason
to favor one type of gas over another.
Patients wore loose clothing, slacks, or shorts and
brought two pairs of support hose to the injection sessions.
Patients were asked not to shave or apply lotion to their legs
the morning before the injections. Emphasis was placed on
postinjection compression. The patients were instructed to
wear two pairs of compression hose during the day for the
first 48 hours and to sleep with one pair only for those two
nights. Shower was allowed but hose had to be reapplied
promptly. Patients had to take, at a minimum, a brisk
30-minute walk every day in their support hose. Normal
activities were resumed immediately after injection with the
support hose in place. Strenuous activity had to be avoided
for 2 days.Weight lifting had to be avoided for 2 weeks, and
hot baths, hot showers, saunas, steam rooms, and whirlpool
type tubs for 2 to 3 weeks. Prescribed baby aspirin were
taken and patients could take acetaminophen for pain or
discomfort. A list of anti-inflammatory medicines not to be
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vitamin E supplements were to be avoided for 2 days before
and 2 weeks after injections. The patient spent most of the
first hour after treatment getting ready with support hose,
dressings, and performing mild activity in the clinic while
receiving detailed instructions. This basic protocol was
similar to all patients in the air- and CO2-based foam
groups.
Statistical analysis. Vital signs comparisons were per-
formed using the paired t test provided with the Excel
program (Microsoft, Inc, Seattle, Wash). Incidence of side
effects and adverse events observed for the air- or CO2-
based foam groups were compared using the 2 program
also provided with the Excel program.
RESULTS
After injection of air- or CO2-based foam, there were
no physiologically significant changes in vital signs or in the
electrocardiogram (Table I). However, statistically signifi-
cant differences were noted in the following vital signs
measured at base line and during foam injection:
(1) during air-based injection, the average decrease of 4
bpm in heart rate was significant (P  .001 by paired
t test); and
(2) during CO2-based injection, the average decreases of 3
bpm in heart rate (P  .001), 4 mm Hg in systolic
blood pressure (P  .001), and 2 mm Hg in diastolic
blood pressure (P  .03) were significant by paired
t test.
Localized itching was reported by 6% (3/49) and by
15% (19/128) of the patients receiving air- or CO2-based
foam injections, respectively (P  .12). Localized pain was
reported by 22% (11/49) and by 20% (26/128) of the
patients in the air- and CO2-based foam groups, respec-
tively (P  .75).
Table II presents the incidence of side effects and
complications following air- or CO2-based foam sclero-
Table I. Vital signs associated with chemical ablation
Ultrasound-guid
Liquid: 1
Gas: air or car
Preprocedure
Air-based foam
Heart rate (bpm) 77  10 (SD)
Respiratory rate (rpm) 19  3
PO2 (%) 98  2
Systolic pressure (mm Hg) 127  16
Diastolic pressure (mm Hg) 79  11
CO2-based foam
Heart rate (bpm) 75  12
Respiratory rate (rpm) 14  4
PO2 (%) 98  2
Systolic pressure (mm Hg) 128  16
Diastolic pressure (mm Hg) 76  11therapy. Chest tightness, dry cough, and dizziness de-creased significantly by substituting CO2 for air as a gas to
form the sclerosing foam.
Average air-based foam volumes injected in patients
reporting vs patients not reporting (1) chest tightness,
29  11 (SD) vs 26  10 mL, (2) dizziness, 26  11 vs
26 10 mL, or (3) leg pain, 28 10 vs 26 10 mL, were
not statistically significantly different (P  .37). A statisti-
cally significant higher volume was injected in patients
reporting vs not reporting dry cough, 35 9 vs 24 9 mL
(P .005). No side effects or complications listed in Table
II were reported by five patients receiving less than 15 mL
of air-based foam. The four patients reporting visual distur-
bances received 27, 17, 15, and 15 mL of air-based foam.
Average CO2-based foam volumes injected in patients
reporting vs patients not reporting (1) events listed in Table
II, 27  14 (SD) vs 24  11 mL, or (2) leg pain, 23  9
(SD) vs 25  12 mL, were not statistically significantly
different (P  .36). The four patients reporting visual
disturbances received 8, 16, 18, and 40 mL of CO2-based
foam.
The figure reports and compares the probability of
m sclerotherapy
idocanol
ioxide (CO2)
15 min into procedure 60 min postprocedure
73  8 68  10
19  4 19  3
97  2 98  1
129  15 124  15
80  12 74  9
72  10 71  11
14  4 14  4
98  2 98  2
124  16 125  16
74  12 72  12
Table II. Side effects following chemical ablation
Ultrasound-guided foam sclerotherapy
Liquid: 1% polidocanol
Gas: air or carbon dioxide (CO2)
Condition
Gas
2Air CO2
Chest tightness 9 (18%) 4 (3.1%) P  .001
Dry cough 8 (16%) 2 (1.6%) P  .001
Dizziness 6 (12%) 4 (3.1%) P  .019
Visual disturbance 4 (8.2%) 4 (3.1%) P  .15
Metallic/medicine taste 0 (0%) 2 (1.6%) P  .39
Nausea 2 (4%) 3 (2%) P  .53
Circumoral paresthesia 0 (0%) 1 (0.8%) P  .53
Respiratory difficulty 0 (0%) 1 (0.8%) P  .53
Total 49 (100%) 128 (100%)ed foa
% pol
bon doccurrence of chest tightness, dry cough, and/or visual
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not occur if the volume of foam injected was less than
15-16 mL. Above these values, the event probability was
not related to volume injected. In these studies, however,
only five (10%) and 15 (12%) patients in the air- and
CO2-based groups had such low volumes injected. A 30%
to 40% incidence of such events with air-based foam de-
creased to less than 10% if CO2 were used rather than air.
In summary, 39% (19/49) and 11% (14/128) of the
patients in the air- and CO2-based foam groups, respec-
tively, reported events listed in Table II (P  .001). With
the exception of one patient in the CO2 group reporting
nausea, all these events cleared within 24 hours.
DISCUSSION
The evolution from visual liquid sclerotherapy to (1)
ultrasound-guided liquid sclerotherapy, (2) air-based foam,
and, presently, (3) amore physiological gas, eg, CO2- based
foam has growing evidence presented in the literature. The
safety profile studies performed in our own clinic also
favored the use of a physiologic gas, CO2, to create the
foam needed for chemical ablation of insufficient superficial
veins of the lower extremity.
In our practice, transitions occurring in chemical abla-
tion have been monitored clinically, physiologically, and
ultrasonographically. The nurses involved in the recording
of events had several years of experience in dealing with
patients being treated in an outpatient phlebology clinic.
Of interest in the methodology employed, the patients did
not receive suggestions of signs, or symptoms being inves-
tigated. Any description of side effects had to be volun-
teered by the patient. Some events, specifically dry cough,
were observed directly while the patients were still in the
clinic. Transthoracic echo (TTE) and transcranial Doppler
(TCD) have been employed to demonstrate if a foramen
ovale is patent and if bubbles can reach the brain.36 This
study with CO2-based foam, as well as its predecessor with
air-based foam, was designed to record the patients’ vital
signs, side effects, and adverse reactions following a pro-
Fig. Endovenous chemical ablation: event probability as a func-
tion of air- or carbon dioxide (CO2)-based foam sclerotherapy
with volumes less than indicated in the horizontal axis.spective, monitored protocol.The incorporation of foam sclerotherapy was based on
reports describing a broad international experience. Feasi-
bility, effectiveness, efficacy4,6,17-19,21,23-29,31,34,37-39 and
comparative5,7,10,12-16,20,22,40-41 studies have been con-
ducted in many countries and distinct continents. The
transition from air to a physiologic gas has been supported
by the experience of Cabrera in Spain and by the interna-
tional trials conducted by Provensis to test the physiologic
mix Varisolve.3-7,18,23,29 In particular, Cabrera et al have
injected larger amounts of physiological foam than those
recommended by consensus based primarily on air-based
foams.11 This study and our general experience are in
accordance with the injection of large volumes of foam.
The events described were not directly related to the vol-
ume of foam used. Only dry cough with air-based foam had
a relation to foam dosage.
Side effects, adverse reactions, and minor or major
complications following foam sclerotherapy have been lim-
ited in incidence and in duration. Different objectives,
varying descriptions, and low incidence make it difficult to
analyze the information presented in the literature. Most
published reports described experiences with air-based
foam. The following is a summary of observations similar to
the ones described in this work relating adverse events.
Adverse events: air-based foam. Visual disturbances
or scotomas have been a major focus of attention when
evaluating adverse events following foam sclerotherapy.
Frequencies of occurrence, as mentioned in the litera-
ture, varied from 0% to 6% following air-based foam
injection.15-17,19,21-22,24,26,34,37-38 Most publications
indicated a frequency of less than 1%. Our prospective
evaluation showed frequencies of occurrence of 8% for
air- and 3% for CO2-based foams. The prospective nature
of this study may have resulted in slightly higher find-
ings.
Respiratory difficulties were not reported by our pa-
tients in the air-based foam series, with only one patient
having such problems after CO2-based foam injection.
Pulmonary embolism is a concern, but its occurrence is rare
and may relate more to other patient conditions than to the
procedure itself. Pascarella et al reported one case of pul-
monary embolism occurring 4 months after the proce-
dure.25
Forlee et al reported one case of stroke following vari-
cose vein foam injection sclerotherapy.35 The patient had
an undiagnosed, very large, patent foramen ovale. The
opinion of international experts was that this single episode
should not justify presclerotherapy clearance for patent
foramen ovale or right-to-left shunts.42 Thousands of pa-
tients with patent foramen ovale have been treated with
foam sclerotherapy without adverse events.34 Serious inci-
dents may occur not only after foam sclerotherapy but also
after liquid sclerotherapy or surgical stripping as attested by
the reports on cardiac arrest and brain infarct.32,33 The
practicing phlebologist should have protocols to deal with
such a serious adverse event if one occurs.
Other events included in this investigation have been
rarely reported. A prospective study like ours, focusing on
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evaluations. The following are some comments about the
events listed in Table I.
Chest thightness was mentioned by Bergan et al as an
adverse event; only a few of their patients described this
condition.26 In our studies, chest thightness occurred with
a significant frequency when air-based foam was used, 18%,
and decreased significantly to 3% when CO2-based foam
was administered.
Dry cough was also mentioned by Bergan et al as an
adverse event that occurred infrequently.26 Our study also
had a higher frequency with air-based foam, 16%, decreas-
ing to less than 2% with CO2-based foam.
Dizziness apparently has not been formally reported or
investigated in a prospective manner. Alos et al indicated
that none of their patients had dizziness.15 We found a
significant frequency of 12% with air-based foam that de-
creased to 3% with CO2-based foam.
Nausea also has not been formally reported after a
prospective evaluation. In our studies, the frequency of
nausea was relatively small and the decrease with the change
in gas was not statistically significant.
Metalic or medicinal taste has not been formally evalu-
ated or described. This event occurred twice after CO2-
based foam injection, and, perhaps, should not influence
daily practice.
Paresthesia was also mentioned by Bergan et al as
occurring infrequently.26 In our evaluation, no patient
reported paresthesia. Minimizing this event seems to be a
major advantage of foam-based chemical ablation when
compared with surgical stripping.
Other events have been described in the literature.
True migraine or occular migraine was experienced by a
couple of patients as described by Bergan et al.26 Transient
confusion had a frequency of about 1% according to Frullini
et al.19 Neurasthenia has been reported but with an insig-
nificant frequency.21,24
The frequencies of occurrence of tissue necrosis have
been reported as less than 2%.19,26,31 Tissue necrosis can be
insignificant in general, but it can have a significant inci-
dence when varicose vein patients are excluded from the
calculation.26-30 Tissue necrosis occurred in about 1% of
patients with skin changes and ulcers (CEAP clinical classi-
fication C4 to C6), perhaps between 1% and 10% for a small
group of patients with open ulcers, or in close to 17% (1/6)
in patients with angiomata. The later statistics are affected
by the small number of cases but raise the concept that
adverse event frequencies are dependent on the conditions
of the patients. Improved care must take into consideration
the frequency of events in very specific populations.
Venous thrombosis has been reported as expected. This
adverse event can be separated in four major groups: (1)
extensive deep venous thrombosis involving the femoro-
popliteal veins; (2) thrombus extension into a small seg-
ment of the common femoral or popliteal vein; (3) deep
venous thrombosis limited to calf veins; and (4) superficial
thrombophlebitis.Extensive femoropopliteal thrombosis following chem-
ical ablation has been rare. A preprocedure clinical history
for familial and individual, hypercoagulable states, most
likely, can minimize occurrences of this event.2 Extension
of thrombosis to the femoral or popliteal veins has been
described by several authors with an incidence of less than
2%.16,19,37-39 Calf thrombosis limited to the posterior tibial
or gastrocnemius veins has also been described with an
incidence varying from near 0% to 4%.16,21,24-26,38 Such
frequencies may also be dependent on the overall condition
of the patient and may be lower for patients with simple
varicose veins compared with patients with advanced
chronic venous insufficiency.
Superficial thrombophlebitis, in principle, should be
considered a direct consequence of the treatment. This
finding, however, is considered an adverse event if throm-
bophlebitis extends beyond the region treated or if the
inflammation is significantly worse than commonly ex-
pected. Therefore, one should expect the reports to be
highly variable and subject to individual interpretation.
Incidences have been reported varying from 1% to 11%, or
even 33% for a specific population with reflux starting in the
veins at the groin.14,17,19,31,37-38 Significant inflammation
has occurred with an incidence close to 5%.10,21,24
Hamel-Desnos described the incidence of hematomas
at about 2%.10 Frequency of telangiectatic matting was
insignificant according to Barrett et al.21,24
Adverse events – CO2-based foam. CO2 has not
been used as much as air and the literature on adverse
events reflects such a pattern. The experience of Cabrera’s
group and findings of the Provensis international research
are summarized below.
Transient visual disturbances and dry cough were de-
scribed by two patients each for an incidence of less than
2%.23 This report indicates usage of 20 to 30mL of foam to
treat the saphenous vein. The mixed gas used was primarily
CO2 andO2. Coughing, inflammation, and photopsia were
reported in 2001.18
Treatment of venous malformations was performed
with volumes up to 80 mL.29 Skin necrosis was an adverse
event in 6% of the patients. An injection in a small arterial
branch was reported. Deep venous thrombosis, pulmonary
embolism, or neurological symptoms did not occur as
mentioned in the 2000, 2001, and 2003 reports.4,18,29
Apparently CO2-based foam does not increase the risk
of deep venous thrombosis. Anecdotal descriptions of
thrombosis in calf veins near treatment sites have been
mentioned. Superficial thrombosis has also been reported.
The incidence of significant superficial thrombophlebitis
was 10%.23
The Varisolve report of 2006 describedmild contusion,
skin discoloration and limb pain.7 A very small proportion
of transient paresthesias, or visual and speech disorders
occurred with Varisolve. Cardiopulmonary adverse events
suggestive of gas embolism did not occur. Incidence of
headache was similar for the Varisolve vs saphenous strip-
ping comparison, or for the Varisolve vs other sclerotherapy
comparison. In total, however, the frequency of headaches
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curred in 4.5% of the Varisolve patients in the surgery
comparison group and 0.8% in the sclerotherapy compari-
son group. This adverse event did not occur after changes
in protocol requiring less volume and compression when
foam approached the saphenofemoral or popliteal junc-
tions.
In summary, this cohort study evaluated a physiological
gas alternative for endovenous chemical ablation. Compar-
ison with historical control was performed in a stable clin-
ical population treated with similar volumes of foam for
similar varicose vein problems. Heart rate, respiratory rate,
electrocardiogram, and pulse oximetry were not physiolog-
ically affected by UGFS. This report confirmed the low
incidence of visual disturbances and respiratory distress that
may occur after UGFS. It documented a significant de-
crease in chest thightness, dry cough, and dizziness when
carbon dioxide replaced air. For volumes greater than 15
mL, incidence of complications or side effects were not
directly related to volume of foam injected; compared with
air, use of CO2 resulted in a three-to fourfold decrease in
chest tightness, dry cough, and/or visual disturbance. Use
of a physiological gas can minimize short-term side effects
associated with foam sclerotherapy of superficial veins of
the lower extremity.
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